Reshaping the HIV treatment and prevention landscape
Deployed digital and predictive analytics to further enhance outcomes
gsk
Leading Share of Voice (%)
across key products
Bexsero
Shingrix
US Trelegy: 47% increase in
Rx when omnichannel
approach deployed
Average NRx per 100 HCPs
(Normalized vs HCPs Receiving no Promotion)
Oct 2020 Dec 2020
-
521
Benlysta: Combination of
predictive analytics and medical
engagement unlocking
medical need
Number of patients with reduction in MUN
0
6 Months Post
12 Months Post
Blenrep
Zejula
Nucala
Trelegy (Allergists)
Trelegy
(Pulmonologists)
109
86
355
No Promotion Only Digital
Only Field Field & Digital
0%
50%
100%
GSK (US, March'21) 2nd Competitor
Source: Nucala, Trelegy, Shingrix, Bexsero SOV from IQVIA SMART
Promotional Insights Monthly SOV.
Zejula SOV data from BrandImpact, weekly R4W average through Mar 2021.
Source: GSK US Internal analysis
Total number of patients with addressed MUN
-200
-400
-400
-600
-600
-700
-800
-1000
-1200
-1000
-1200
No biologic treatment
Disease progression
Excessive Steroid Use
Source: Benlysta Medical Unmet Need Programme; McKinsey & GSK
internal analysis; Data through December 2020
31View entire presentation